Top-line results from phase 3 focus trial of Kyrpolis®

AMGEN ANNOUNCES TOP-LINE RESULTS FROM Phase 3 FOCUS TRIAL of KYPROLIS® IN PATIENTS WITH RELAPSED AND ADVANCED REFRACTORY MULTIPLE MYELOMA THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. (Aug. 13, 2014) – Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The…

World Cancer Report 2014

Edited by Bernard W. Stewart and Christopher P. Wild This book from the International Agency for Research on Cancer, the specialized cancer agency of the World Health Organization, provides a unique global view of cancer, including cancer patterns, causes, and prevention. The World Cancer Report series is recognized as an authoritative source of global perspective and information on cancer. The first volume appeared in 2003 and the second in 2008. This third volume in the…

Eurocare 5 Results

EUROCARE 5 results where presented at the European Parliament on 5 December 2013. Some of the conclusions were: • The number of adults survive at least 5 years after diagnosis has increased steadily over time in all regions of Europe from 1999 to 2007 , BUT STILL cancer survival varies widely between European countries.

EHA survey on unavailability of medicines

A website survey where doctors, patients and healthcare professionals can report unavailability of medicines has been developed. Over the course of (at least) the following months, these reports will be collected and analysed so that we can develop a coherent picture of the scope, causes and consequences of these problems in Europe. At the moment such an overview does not exist which makes it difficult for European politicians and policy makers to take measures that…

Lithuanian Presidency to start negotiations on clinical trials regulation

The Committee of Permanent Representatives (COREPER I) mandated the Lithuanian Presidency to enter into negotiations with the European Parliament and the Commission with the aim to reach an agreement at first reading on the Proposal for a Regulation on Clinical trials on medicinal products for human use, which aims to facilitate the conduct of clinical trials and thus increase their number in the EU, which could result in better treatment of patients.

Amendments to the pharmacovigilance legislation: new notification requirements for marketing-authorisation holders and changes to scope of European safety referrals

Amendments of the European Union (EU) pharmacovigilance legislation that were adopted in October 2012 came into force on Monday 28 October 2013. These changes, which cover various aspects of the legislation, aim to further strengthen the protection of patient health by increasing the ability of the European medicines network to take prompt and appropriate regulatory action.